BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16328065)

  • 21. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
    Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I
    Anticancer Res; 2005; 25(5):3645-9. PubMed ID: 16101195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
    Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
    Arai T; Fujita K; Fujime M; Irimura T
    Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
    Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK
    Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
    Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostate cancer detection by prostate biopsy among Japanese with prostate-specific antigen below 4.0 ng/ml].
    Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
    Hinyokika Kiyo; 2006 Mar; 52(3):181-4. PubMed ID: 16617870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
    Coard KC; Skeete DH
    BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris.
    Namazi MR; Fallahzadeh MK; Shaghelani H; Kamali-Sarvestani E
    Int J Dermatol; 2010 Feb; 49(2):146-8. PubMed ID: 19799642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.
    Khan N; Cromer CJ; Campa M; Patz EF
    Cancer; 2004 Jul; 101(2):379-84. PubMed ID: 15241837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.